Novo Nordisk's acquisition of the US-based biotech company for USD 3.3bn follows a two-year-long successful collaboration, and signals that more drug candidates from Dicerna's technology platform targeting Novo's focus areas could be on their way in the future, says Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk, to MarketWire.
The biotech company, which is based in Lexington, has specialized within RNA interference (RNAi), a technology where specific genes are suppressed before they can produce proteins that contribute to disease progression.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Zealand Pharma sells shares for over USD 100m
With a 5% discount, the biotech company managed to sell 4,975,000 of its own shares in a direct issuance.
Zealand Pharma CEO: Share sale arms us for partnership negotiations
After a study success with short bowel syndrome treatment candidate, the Danish biotech company raised funding by issuing shares, preparing the company’s CEO, Adam Steensberg, to enter dialogs with a number of potential partners.
Complete company divestment is not part of Zealand Pharma's strategy
After a Nordnet analyst brought up the possibility of the Danish company being an acquisition target for foreign firms, CEO Adam Steensberg has ruled out the notion of a full sale.
Three scientists share chemistry Nobel for cancer improvement technology breakthrough
Danish national Morten Meldal and two colleagues have been awarded the prestigious award for their research into click chemistry, which is used the development of cancer drugs.
Audientes builds on Q2 momentum, maintains guidance
The hearing aid company has sold self-fitting hearing aids for over DKK 2m (USD 266,700) during the third quarter that ended in September.
Senior Drug Product Specialist 
Senior/lead consultant at Emendo Engineering 
Scientist Radiochemistry 
Head of department RA/QA/PV, Danmark 
KLIFO is looking for a Compliance Coordinator for our Glostrup office 
Pharmacovigilance & Regulatory Assistant with an interest in non-fiction 
Lab Manager 
Nordic Key Account Manager, Hollister & Dansac 
Chief Business Officer 
Calibration Technician 
Product specialist 
Upstream Processing CMC Specialist 
Orifarm Healthcare Product Development PMO Director